Evidence supporting the use of: Catecholamine
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Catecholamines, such as dopamine, dobutamine, and norepinephrine, are scientifically validated for use in certain cases of congestive heart failure (CHF), particularly in acute or severe decompensated heart failure where there is evidence of low cardiac output and poor end-organ perfusion. These agents act as inotropes and vasopressors, increasing cardiac contractility and, depending on the specific catecholamine, altering vascular tone. The use of catecholamines in CHF is supported by robust physiological rationale and clinical experience, though their use is generally limited to short-term management in critical care settings due to the risk of arrhythmias, increased myocardial oxygen consumption, and potential for worsening long-term outcomes. Major cardiology guidelines (e.g., American Heart Association, European Society of Cardiology) recommend intravenous catecholamines for patients with acute heart failure and signs of hypoperfusion or cardiogenic shock who do not respond to other therapies. However, their use is not recommended for chronic CHF management due to a lack of evidence for long-term benefit and the potential for harm. Clinical trials and observational studies have demonstrated improvement in hemodynamic parameters with catecholamine use, but also highlight increased risks if used beyond the acute setting. In summary, catecholamines have a well-established, evidence-based role as short-term, life-saving interventions in acute decompensated heart failure with low output states, but are not suitable for long-term treatment.

More about catecholamine
More about Congestive Heart Failure

Products containing catecholamine

We currently have no products on Vitabase that contain this ingredient.